Finance

Lists
Q1 2027 earnings • in 5 days
See details
3349:TYO
Cosmos Pharmaceutical Corp
6 301,00 JP¥
-0,41%
(-26,00) 1D
8-окт., 11:30:00 GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 3349...
Open
6 399 JP¥
High
6 406 JP¥
Low
6 271 JP¥
Mkt. cap
505,43 млд
Avg. vol.
433,65 миң
Volume
104,60 миң
Dividend
1,30%
Quarterly dividend
21 JP¥
Ex-dividend date
2026-ж., 27-ноя.
P/E ratio
15,58
52-wk high
8 590 JP¥
52-wk low
5 615 JP¥
EPS
404 JP¥
Shares outstanding
19,80 млн
No. of employees
6 миң
Open
6 399 JP¥
High
6 406 JP¥
Low
6 271 JP¥
Mkt. cap
505,43 млд
Avg. vol.
433,65 миң
Volume
104,60 миң
Dividend
1,30%
Quarterly dividend
21 JP¥
Ex-dividend date
2026-ж., 27-ноя.
P/E ratio
15,58
52-wk high
8 590 JP¥
52-wk low
5 615 JP¥
EPS
404 JP¥
Shares outstanding
19,80 млн
No. of employees
6 миң
News stories
From web sources and news partners
Simply Wall Street
Simply Wall Street
·
18 мүнөт мурун
Twilio (TWLO) Joins The S&P 500, Does It Look Fully Valued?
Seeking Alpha
Seeking Alpha
·
1 саат мурун
What Happened To The Banks
Investor's Business Daily
Investor's Business Daily
·
31 мүнөт мурун
Futures: Memory Giant's Earnings Surge, But Miss Views
About Cosmos Pharmaceutical Corp
CEO-
Employees5,98 миң
Foundedдек. 1983
Headquarters-
SectorDrug
Next call 5 күндөн кийин
13-окт., шейш., 00:00
Fiscal period
Q1 2027
- / -
Revenue / Est. (JPY)
- / 291,21 млд
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
2025-ж. авг.
2025-ж. ноя.
2026-ж. фев.
2026-ж. май
Revenue
272,39 млд
264,78 млд
273,20 млд
289,20 млд
Cost of goods sold
215,22 млд
209,07 млд
216,15 млд
229,46 млд
Cost of revenue
215,22 млд
209,07 млд
216,15 млд
229,46 млд
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
45,64 млд
46,57 млд
45,83 млд
26,43 млд
Operating expense
45,64 млд
46,57 млд
45,83 млд
49,08 млд
Total operating expenses
260,86 млд
255,64 млд
261,97 млд
278,54 млд
Operating income
11,54 млд
9,14 млд
11,23 млд
10,66 млд
Other non operating income
627,00 млн
801,00 млн
667,00 млн
695,00 млн
EBT including unusual items
12,09 млд
9,58 млд
11,96 млд
10,60 млд
EBT excluding unusual items
12,08 млд
9,85 млд
11,81 млд
11,12 млд
Income tax expense
3,92 млд
3,10 млд
3,86 млд
1,30 млд
Effective tax rate
32,40%
32,35%
32,26%
12,26%
Other operating expenses
-
-
-
-
Net income
8,17 млд
6,48 млд
8,10 млд
9,30 млд
Net profit margin
3,00%
2,45%
2,96%
3,21%
Earnings per share
-
-
-
-
Interest and investment income
27,00 млн
19,00 млн
16,00 млн
12,00 млн
Interest expense
-110,00 млн
-107,00 млн
-107,00 млн
-257,00 млн
Net interest expenses
-83,00 млн
-88,00 млн
-91,00 млн
-245,00 млн
Depreciation and amortization charges
-
-
-
22,64 млд
EBITDA
17,09 млд
15,00 млд
16,79 млд
16,81 млд
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google колдонмолору